<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9"><gtr:id>31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9</gtr:id><gtr:name>MRC Human Immunology Unit</gtr:name><gtr:address><gtr:line1>Weatherall Inst of Molecular Medicine</gtr:line1><gtr:line2>John Radcliffe Hospital</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 9DS</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9"><gtr:id>31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9</gtr:id><gtr:name>MRC Human Immunology Unit</gtr:name><gtr:address><gtr:line1>Weatherall Inst of Molecular Medicine</gtr:line1><gtr:line2>John Radcliffe Hospital</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 9DS</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A9A12AFB-52DD-481B-A639-8F98B1C69AA1"><gtr:id>A9A12AFB-52DD-481B-A639-8F98B1C69AA1</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>McMichael</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U137884177"><gtr:id>5A6FB596-9C6B-4491-8192-13FA677AEAF5</gtr:id><gtr:title>T cell immune responses to viruses</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U137884177</gtr:grantReference><gtr:abstractText>These studies continue our detailed investigation into how the T cell immune response controls and in some cases eliminates virus infections. ||The mains focus is on HIV infection where there is a complex interplay between virus and the immune system. Besides infecting key cells of the immune system, HIV interferes with immune cell functions by cell surface interactions (Simmons). Also, because it is so variable HIV can readily escape by mutation at the sites in the proteins that are recognised by immune cells (Iversen). These pose difficult questions for vaccine design and it is essential to know more about the very first immune responses in HIV infection and whether these are undermined (Goonetilleke). ||We are involved in making vaccines to HIV and studying these in clinical trails, not only for prevention but also treatment of HIV infection (Dorrell). ||Lastly we have increased our interest in influenza, because of the threat of a new pandemic, and are studying T cell responses to this virus (Ho, and see also Dong and Xu). ||We have had a lot of media attention both for the AIDS and influenza work. Professor McMichael contributes to national and international forums frequently.</gtr:abstractText><gtr:technicalSummary>Five programmes on T cell immune responses to viruses are interlinked but distinct.||Dr Iversen is working on HIV-1 escape from CD8 T cell responses. We were first to such show virus escape in 1991 and this is now well established, but its role in AIDS pathogenesis is poorly understood. We have recently concentrated on T cell responses to HIV gag in a region of virus where there is a lot of virus variability and several overlapping epitopes are recognised by immunodominant T cells. We have shown using in vitro immunology, virus sequencing, bioinformatics and statistical approaches that opposing forces act on variable regions of virus, T cells selecting mutants but virus tending to revert to the consensus sequence because of fitness costs. Thus the T cell pressure to escape can lead to better control of virus.||Dr Dorrell is exploring the use of vaccines to treat HIV infection. She has used the DNA and MVA HIVA vaccines constructed by Dr Hanke (and previously tested extensively in vaccine trials in HIV uninfected volunteers) to boost T cell responses in patients who have good control of HIV by antiretroviral drug therapy. Having shown that she can do this in small clinical trials she has initiated a pilot study to investigate whether a vaccine boosted T cell response can better control the virus when ART is interrupted.||Professor McMichael and Dr Goonetilleke are running the NIH Centre for HIV AIDS Vaccine Immunology (CHAVI) programme in Oxford. CHAVI is a very large international consortium aimed at complete understanding the immune responses in acute HIV infection, so as to better design HIV vaccines. Having gained all necessary ethical approvals and built up the cohorts in the first year, the programme is now running. The first aim is to map and measure the CD4 and CD8 T cell responses in very early infection and studying early evolution of virus. Also in collaboration with Dr P Borrow (Jenner, Oxford) we are studying very early innate immune responses.||Dr Simmons is studying one of the earliest events in HIV infection, the interaction with dendritic cells though attachment to the surface glycoprotein DC-SIGN. She has explored HIV triggered signalling from the cytoplasmic domain of DC-SIGN and has shown strong but inhibitory signals are delivered, affecting for example the expression of co-stimulators of the immune responses CD81 and CD83. She has used proteomics to analyse these signalling pathways.||Dr Ho is studying the role of NKT cells, a subset of T cells that produce large quantities of IFN-gamma and IL-4, in influenza virus infection. NK T cells recognise glycolipids presented by CD1d (see Cerundolo and Xu). In the airways in mice in influenza virus infection NKT activity is raised. Currently she is studying their role in human bronchial explants infected with influenza virus. ||Experimental design - Molecular and cellular Immunology||a) tissues, cells, animals used - Human blood and cell lines||b) techniques/approaches - Molecular biology and immunology||c) measurements/outcomes - T cell function</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1998-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3413139</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Center for HIV/AIDS Vaccine Immunology (CHAVI)</gtr:department><gtr:description>CHAVI</gtr:description><gtr:id>BF85D60B-4EC8-4C91-B9B2-CE2C051D324C</gtr:id><gtr:impact>17641165 19487423 19812560 19454339, 22140359, 22711904, 22634443, 22514337, 22513323, 22826228, 22287716, 2269947, 22206265, 23002014, 22095198, 22851641</gtr:impact><gtr:outcomeId>DE3E405A5A9-1</gtr:outcomeId><gtr:partnerContribution>Extensive network of collaborators covering clinical sites, virology, virus sequencing, bioinformatics, mathematical modeling</gtr:partnerContribution><gtr:piContribution>I am one of the 7 lead PIs in the NIH Center for HIV AIDS Vaccine Immunology (CHAVI). I head the T cell and innate immunity programme. WE have initiated two studies, one on the cellular immune responses in very early HIV-1 infection (Goonetilleke et al 2009) and the other on the immune responses in people who are exposed to HIV but are uninfected. We have also initiated a genome wide association study of haemophiliacs who were exposed to HIV contaminated Factor VIII wihtoug being infected (with the CHAVI Genetics Core).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>WIMM lectures during Science week each year</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F23874C1-C5FD-4970-BC00-6F004BB33E54</gtr:id><gtr:impact>4-5 lectures are held each year in March during national Science Week.

Steadily increasing audience each year from c50 in 2006 to 120 in 2009</gtr:impact><gtr:outcomeId>A2229DFBF7B</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interactions with Media</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6B1596DA-7CCB-45F6-9EFF-A2E21B5FED1E</gtr:id><gtr:impact>Interviewed by BBC Dec 2006, Radio Oxford March 2007, Science Media Centre March 2007, Podcast interview March 2007, Chinese radio Feb 2008, BBC June 2008, Australian radio Fen 2009, BBC July 2009, BBC Sept 2009

Hard to tell. No feedback received but have been contacted repeatedly by BBC in particular.</gtr:impact><gtr:outcomeId>7FD9D870294</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>197000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical training fellowship, C Sargent</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D076D47C-1921-4A24-B3B3-CEABD0076F9D</gtr:id><gtr:outcomeId>75056AD4F860</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>266000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Fluwatch</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8F79AE76-B8D7-494A-A856-CC481E29C186</gtr:id><gtr:outcomeId>778DDE243450</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>216188</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Training Fellowship T Corrah</gtr:description><gtr:end>2010-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>89D56BB5-CE19-454E-8B43-338591A9AAE5</gtr:id><gtr:outcomeId>7374E29BFF10</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>644000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Clinician Scientist Alison Simmons (U Oxford)</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>F36C9DAC-BF04-4F6E-B54C-B6CEBBDFC0BE</gtr:id><gtr:outcomeId>AF4749AA8C70</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>244000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Fellowship</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3BC581EE-E166-46A4-957E-AA4A690A65D7</gtr:id><gtr:outcomeId>B03EB485BEE0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>844000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Clinician Scientist LP Ho</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>6E109CB7-472B-474C-B64E-CB1E53745608</gtr:id><gtr:outcomeId>603EE56F3210</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2500000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIH CHAVI (USA)</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>EEE81A0E-8C63-471E-BA26-A33100556124</gtr:id><gtr:outcomeId>418EC8852ED0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>Japan</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>JHSF Funding</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Japan Health Sciences Foundation</gtr:fundingOrg><gtr:id>E6A6D0D9-AAD0-4C66-99E6-DA834FE5D143</gtr:id><gtr:outcomeId>AAA87D7C2440</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTC-VIMC)</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>Foundation for the National Institutes of Health (FNIH)</gtr:fundingOrg><gtr:id>BCD9CFBB-E9DA-4678-B39D-B22643CC9D92</gtr:id><gtr:outcomeId>DEB2A34EA3A0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>299859</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Influenza Grant</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1F46BA0B-7275-43D5-90DA-D94E35933BCF</gtr:id><gtr:outcomeId>663AD82F6290</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>506450</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Experimental Medicine</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8E1C87E3-A538-4201-8BA0-181D76EC3D0C</gtr:id><gtr:outcomeId>981D4377D670</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WT Post doctoral research fellowship A Leslie</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>0D93C10D-DC91-4225-831B-34B9B68A39DD</gtr:id><gtr:outcomeId>EAD15B6F13D0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>323116</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>New Investigator Fellowship</gtr:description><gtr:end>2009-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9214AC07-9FE1-4C4C-844B-19D4F0F459CC</gtr:id><gtr:outcomeId>2D67E7FEC6B0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>HIV Consv is a DNA construct that comprises the 14 most conserved regions of the HIV-1 genome. It has been inserted into a range of recombinant vaccine formats and has been shown to be highly immunogenic in mice and non-human primates. Phase I clinical trials with the vaccine will begin in 2010.</gtr:description><gtr:grantRef>MC_U137884177</gtr:grantRef><gtr:id>0ABCB4D5-5B7D-4E80-87C3-2075767D0980</gtr:id><gtr:impact>Publication 17912361 and subsequent presentation at scientific meetings including the 2009 HIV Vaccine Conference.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>FC71F5D9AC5</gtr:outcomeId><gtr:patentId>US2008089901</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Universal HIV vaccine</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Royal society, Academy of Medical Sciences Pandemic influenza report</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>C3C655FF-9196-4024-AB03-0680387C14BD</gtr:id><gtr:impact>May have influenced decision of Department of Health to stockpile Tamiflu and/or Ralenza for 100% of population of UK. May have influenced MRC to set up FLuwatch</gtr:impact><gtr:outcomeId>30E4847C613</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>HIV-Consv is a synthetic gene based on the 14 most conserved regions of HIV-1. It stimulates T cell responses that react equally with the four major clades of HIV-1 and the virus is less likely to escape from these T cells by mutation.</gtr:description><gtr:id>FAAC812B-AC6B-4C19-9FC7-25B6526495FB</gtr:id><gtr:impact>The initial work was published in 17912361 Patent</gtr:impact><gtr:outcomeId>717B1E16FE2</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>HIV-Consv</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>021432A1-366C-4BAC-9E88-F76FCDBFC33D</gtr:id><gtr:title>New templates for HIV-1 antibody-based vaccine design.</gtr:title><gtr:parentPublicationTitle>F1000 biology reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a41215f2cd047676351cc10a4a031ae9"><gtr:id>a41215f2cd047676351cc10a4a031ae9</gtr:id><gtr:otherNames>Sattentau QJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1757-594X</gtr:issn><gtr:outcomeId>Cdh6n7zvWgi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>585B90EF-E1F6-4218-A5F9-E4E9A02E7591</gtr:id><gtr:title>Improved detection of latent Mycobacterium tuberculosis infection in HIV-1 seropositive individuals using cultured cellular assays.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e3acaacb78772163564cfbeca3c916b"><gtr:id>3e3acaacb78772163564cfbeca3c916b</gtr:id><gtr:otherNames>Campion S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>B9K6AeSGsVN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C3B3794-9928-4DDB-B6AF-989169EC9DF7</gtr:id><gtr:title>Human naive CD8 T cells down-regulate expression of the WNT pathway transcription factors lymphoid enhancer binding factor 1 and transcription factor 7 (T cell factor-1) following antigen encounter in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db686f72dfc1fe57861ba687b6d5a1bb"><gtr:id>db686f72dfc1fe57861ba687b6d5a1bb</gtr:id><gtr:otherNames>Willinger T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>1BE103F1810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A472AC5-29B4-41BD-BB00-7CD61EBEFA57</gtr:id><gtr:title>Rational development of high-affinity T-cell receptor-like antibodies.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bd7185a0698864c4440b2dbd1fed93"><gtr:id>a3bd7185a0698864c4440b2dbd1fed93</gtr:id><gtr:otherNames>Stewart-Jones G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>erpswjor3Qi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F90E065-C1A7-43DB-9DE0-6A3CCE48D7FB</gtr:id><gtr:title>Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31d220dbec710abf8b85c06d553c2f4b"><gtr:id>31d220dbec710abf8b85c06d553c2f4b</gtr:id><gtr:otherNames>Fischer W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>bYcwuxoAAQ6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8AD763B-2065-45BF-9C83-EBE3162BF938</gtr:id><gtr:title>The immune response during acute HIV-1 infection: clues for vaccine development.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14eeb8916c21a02f9a4f13433a8408c8"><gtr:id>14eeb8916c21a02f9a4f13433a8408c8</gtr:id><gtr:otherNames>McMichael AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>iqGjaGkqQJk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76653C33-F6BF-4F1A-B6D3-AD16893197FC</gtr:id><gtr:title>Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb73a1601c2776118c87e5253b8af8b2"><gtr:id>cb73a1601c2776118c87e5253b8af8b2</gtr:id><gtr:otherNames>Hodges A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>F6532395014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBFE3BC7-3695-40D6-85E8-71871F1E581F</gtr:id><gtr:title>Reappraisal of the relationship between the HIV-1-protective single-nucleotide polymorphism 35 kilobases upstream of the HLA-C gene and surface HLA-C expression.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/735dbb39429f18571af6ec4671a197b0"><gtr:id>735dbb39429f18571af6ec4671a197b0</gtr:id><gtr:otherNames>Corrah TW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>MrhQjpQ8weG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDD704CE-1072-4C92-8C0E-7A9E358C013A</gtr:id><gtr:title>Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9466a846dc46e4bf8f9c6f67d135c68c"><gtr:id>9466a846dc46e4bf8f9c6f67d135c68c</gtr:id><gtr:otherNames>Freel SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_14011_21_22514337</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>807BA756-0671-4321-B3DC-C27CF3F997D0</gtr:id><gtr:title>Extensive HLA-driven viral diversity following a narrow-source HIV-1 outbreak in rural China.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c22f4dff265ae6494e8c07966c893b13"><gtr:id>c22f4dff265ae6494e8c07966c893b13</gtr:id><gtr:otherNames>Dong T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>jFWFhU16bZH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5487779A-AECA-451C-94FA-B09DBD466290</gtr:id><gtr:title>Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac38f1b0dc4a279a2ca4ea99d8d93cfc"><gtr:id>ac38f1b0dc4a279a2ca4ea99d8d93cfc</gtr:id><gtr:otherNames>Karlsson AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>3E2DFB87BCE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7933457F-0733-4B59-8FA0-5748AFDF55C0</gtr:id><gtr:title>Human CD4+ memory T cells are preferential targets for bystander activation and apoptosis.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77853219a8282a297bce024e36ab471c"><gtr:id>77853219a8282a297bce024e36ab471c</gtr:id><gtr:otherNames>Bangs SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>CcQb6QyLRBz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BBFE3DD-6914-40F6-9974-6EB132B092F7</gtr:id><gtr:title>The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/943afd66240b87a716970ccd9ece4a71"><gtr:id>943afd66240b87a716970ccd9ece4a71</gtr:id><gtr:otherNames>Goonetilleke N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>69C65144513</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FDE0347-A437-4B3C-AD8C-A7FCEA266AF8</gtr:id><gtr:title>HIV-1: from escapism to conservatism.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9888e0f37e7d1c89e61cdc32ed5605b0"><gtr:id>9888e0f37e7d1c89e61cdc32ed5605b0</gtr:id><gtr:otherNames>Hanke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_14011_21_22125004</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6514DDDC-C780-4D19-B14C-58CC9BD4BF4A</gtr:id><gtr:title>High clade C HIV-1 viremia: how did we get here and where are we going?</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1764b1c3a83f9a06960d7a3cc7dba18"><gtr:id>f1764b1c3a83f9a06960d7a3cc7dba18</gtr:id><gtr:otherNames>Cohen MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>SEBkr2gKU8r</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F38458BA-6DEC-4629-A3F3-9D291D637519</gtr:id><gtr:title>Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9f5ab962359496d9c21a8818ec01798"><gtr:id>b9f5ab962359496d9c21a8818ec01798</gtr:id><gtr:otherNames>Jaoko W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>4935C20B341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EBB52BC-CDD0-4C99-B55A-B1CE060560E0</gtr:id><gtr:title>Direct relationship between virus load and systemic immune activation in HIV-2 infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0ae9c03e19152fa146debeb3e0a9814"><gtr:id>c0ae9c03e19152fa146debeb3e0a9814</gtr:id><gtr:otherNames>Leligdowicz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>YccgawTiFAC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAC9809A-453C-48A0-AE52-C47E16ED6CB8</gtr:id><gtr:title>Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da746618b1b17a25497b2235af69178a"><gtr:id>da746618b1b17a25497b2235af69178a</gtr:id><gtr:otherNames>Dorrell L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>2CD8665AB79</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD543D8D-653B-4A84-8723-1E8CC7C6D794</gtr:id><gtr:title>Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b816a5f05ad25fcd412ac8bac4fa818b"><gtr:id>b816a5f05ad25fcd412ac8bac4fa818b</gtr:id><gtr:otherNames>Ferrari G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>j571Ehjx18k</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68C38F2D-9585-4D00-9480-DD620F369700</gtr:id><gtr:title>Activation of invariant NKT cells in early phase of experimental autoimmune encephalomyelitis results in differentiation of Ly6Chi inflammatory monocyte to M2 macrophages and improved outcome.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7cdc53e4d61940698b236b86f46c2a7"><gtr:id>b7cdc53e4d61940698b236b86f46c2a7</gtr:id><gtr:otherNames>Denney L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_14011_21_22685310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>817E2F8D-F470-4CAE-B289-75D58899F4E0</gtr:id><gtr:title>Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f761a85fefe6195d7d2541f0758e6a8f"><gtr:id>f761a85fefe6195d7d2541f0758e6a8f</gtr:id><gtr:otherNames>Scherer EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>c8cpiHT9Sj5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FB7A02B-751F-417B-BE26-C89BF34A4011</gtr:id><gtr:title>Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0176ac52f7a3858de3221c9d5a7dfd0a"><gtr:id>0176ac52f7a3858de3221c9d5a7dfd0a</gtr:id><gtr:otherNames>Ondondo BO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>5FD4993294A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20BD025C-B7AB-4715-9287-98742DF5D378</gtr:id><gtr:title>Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/943afd66240b87a716970ccd9ece4a71"><gtr:id>943afd66240b87a716970ccd9ece4a71</gtr:id><gtr:otherNames>Goonetilleke N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>3E8C4244DE1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D025BA9-B231-42D0-A961-D9D5AFB1AF9F</gtr:id><gtr:title>Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9888e0f37e7d1c89e61cdc32ed5605b0"><gtr:id>9888e0f37e7d1c89e61cdc32ed5605b0</gtr:id><gtr:otherNames>Hanke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>2C33669E880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A6A5E41-E3E6-4BC7-B345-AE6BE29090E6</gtr:id><gtr:title>Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6dc8910324a5dc6c58b9fae087cba8e"><gtr:id>c6dc8910324a5dc6c58b9fae087cba8e</gtr:id><gtr:otherNames>Rosario M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>EXipuL8RxBr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A70818B9-6251-4701-A1AA-F4305C420D0A</gtr:id><gtr:title>Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6e95ae915e653271600239431e5a2db"><gtr:id>b6e95ae915e653271600239431e5a2db</gtr:id><gtr:otherNames>Peters BS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>369ECB6523B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>497799EE-075A-4138-BA49-7DCEC616F172</gtr:id><gtr:title>Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2c033e88884d0efadf1d9cb9e044720"><gtr:id>a2c033e88884d0efadf1d9cb9e044720</gtr:id><gtr:otherNames>Ganusov VV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>SChT1ebbGQD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F0A230D-76DD-418D-BEE4-3662785ECC73</gtr:id><gtr:title>A whole-genome association study of major determinants for host control of HIV-1.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b430cb6cad42d67be5e4807f7cf17e7"><gtr:id>9b430cb6cad42d67be5e4807f7cf17e7</gtr:id><gtr:otherNames>Fellay J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>5CFDCCE83C3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>112487E7-95DB-4B8B-9DDD-A5972BD4F65E</gtr:id><gtr:title>Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71247b3e4da43217946b0d0e25e8029d"><gtr:id>71247b3e4da43217946b0d0e25e8029d</gtr:id><gtr:otherNames>Iversen AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>26F5DF8008C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F512325-5778-4AE7-9515-5EC94B9E0064</gtr:id><gtr:title>Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b709ad3b8e7698295cad3772f08cf235"><gtr:id>b709ad3b8e7698295cad3772f08cf235</gtr:id><gtr:otherNames>Guimar?es-Walker A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>BE499343EAD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48BC5DB4-5954-4880-9A77-B4EA7B0BC770</gtr:id><gtr:title>Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e82396dbfe08edd23f071e1a24e22764"><gtr:id>e82396dbfe08edd23f071e1a24e22764</gtr:id><gtr:otherNames>Ritchie AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pW8Sya4UZ6u</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3CB5B85-CB95-4527-86CF-4EAA84C546E0</gtr:id><gtr:title>Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f2bc78d993328353b85908b6d3e4fcd"><gtr:id>4f2bc78d993328353b85908b6d3e4fcd</gtr:id><gtr:otherNames>Im EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>rJFZd1LDvZX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EA09649-E931-4F8E-B2AF-941A363BE712</gtr:id><gtr:title>Increased sequence diversity coverage improves detection of HIV-specific T cell responses.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd6389a31b091d4c7d05bbf55a8e613b"><gtr:id>cd6389a31b091d4c7d05bbf55a8e613b</gtr:id><gtr:otherNames>Frahm N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>4E802341B90</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFB0D3B6-3EE4-431F-8B13-D49462D37F03</gtr:id><gtr:title>Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13c9270163e5a00e5919e9e956c231ab"><gtr:id>13c9270163e5a00e5919e9e956c231ab</gtr:id><gtr:otherNames>Armitage AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>0AEDE0713E2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FC29B2F-22E0-4328-935B-5F61238B9577</gtr:id><gtr:title>Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da746618b1b17a25497b2235af69178a"><gtr:id>da746618b1b17a25497b2235af69178a</gtr:id><gtr:otherNames>Dorrell L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>D0623B10BD9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8532F91-509A-4FCE-AF3F-D44834FD83A0</gtr:id><gtr:title>The T cell repertoire in infection and vaccination: implications for control of persistent viruses.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1700a73c2a1a52c0cb9ee2512988b2b0"><gtr:id>1700a73c2a1a52c0cb9ee2512988b2b0</gtr:id><gtr:otherNames>Davenport MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn><gtr:outcomeId>EFCAD39F464</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A88179A2-1D31-4B28-8DFD-1E974F77A24A</gtr:id><gtr:title>AIDS/HIV. Finding footprints among the trees.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d9125178bea693a9bb3eae81b908265"><gtr:id>7d9125178bea693a9bb3eae81b908265</gtr:id><gtr:otherNames>Klenerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>F26BF0AA11B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C807B96-EDD2-46CE-B817-228917C8CCDA</gtr:id><gtr:title>Acute HIV-1 Infection.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1764b1c3a83f9a06960d7a3cc7dba18"><gtr:id>f1764b1c3a83f9a06960d7a3cc7dba18</gtr:id><gtr:otherNames>Cohen MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>dkkBWD3Vssj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4DEA037-4A40-4A36-A387-78A21CCE08A5</gtr:id><gtr:title>Generation of tumour-rejecting anti-carbohydrate monoclonal antibodies using melanoma modified with Fas ligand.</gtr:title><gtr:parentPublicationTitle>International immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e067e8d445dbbd31448cdcc2eda5fa95"><gtr:id>e067e8d445dbbd31448cdcc2eda5fa95</gtr:id><gtr:otherNames>Simon AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0953-8178</gtr:issn><gtr:outcomeId>A03806BB74C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D22D05E7-F2BA-412F-BBE3-40760141119E</gtr:id><gtr:title>Multilayered defense in HLA-B51-associated HIV viral control.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d895db59e431e55ec84105d0da4fab0d"><gtr:id>d895db59e431e55ec84105d0da4fab0d</gtr:id><gtr:otherNames>Zhang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>U4dhNyUeGd4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19F7CCE2-D57C-44D1-9D25-03B2EA72791E</gtr:id><gtr:title>Genetics. First-class control of HIV-1.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14eeb8916c21a02f9a4f13433a8408c8"><gtr:id>14eeb8916c21a02f9a4f13433a8408c8</gtr:id><gtr:otherNames>McMichael AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>fDp12GNGrUs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7813AB29-1F46-4995-999F-E9D74195E661</gtr:id><gtr:title>Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6728b659ca9047957546c2994120446a"><gtr:id>6728b659ca9047957546c2994120446a</gtr:id><gtr:otherNames>Wilkinson TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>pm_14011_21_22286307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFCEF42B-46A2-4872-8976-58A05EC59374</gtr:id><gtr:title>The antiviral efficacy of HIV-specific CD8? T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b17017d77435c1a577520bb0831fcac"><gtr:id>4b17017d77435c1a577520bb0831fcac</gtr:id><gtr:otherNames>Ranasinghe SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>sDeiUZpE9K7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CFE8CB0-96AB-4583-9C11-51D069B9751D</gtr:id><gtr:title>Identification of self-lipids presented by CD1c and CD1d proteins.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b96d2567771b14c0381886087aad9e6e"><gtr:id>b96d2567771b14c0381886087aad9e6e</gtr:id><gtr:otherNames>Haig NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>quh7RW1RUqE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F031FFAA-E08F-46C2-BD4C-F30C967A649D</gtr:id><gtr:title>HIV vaccines.</gtr:title><gtr:parentPublicationTitle>Annual review of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14eeb8916c21a02f9a4f13433a8408c8"><gtr:id>14eeb8916c21a02f9a4f13433a8408c8</gtr:id><gtr:otherNames>McMichael AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0732-0582</gtr:issn><gtr:outcomeId>748B56EDA98</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20450CA7-58DD-4B1B-A813-9D6DC12A2756</gtr:id><gtr:title>Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7271d887d655ab8bf8e880119ff2237"><gtr:id>a7271d887d655ab8bf8e880119ff2237</gtr:id><gtr:otherNames>Tenzer S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>362D4857554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28C1F7C5-B7AC-414C-8899-FA8DB0071CE5</gtr:id><gtr:title>From influenza to HIV--and back?</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14eeb8916c21a02f9a4f13433a8408c8"><gtr:id>14eeb8916c21a02f9a4f13433a8408c8</gtr:id><gtr:otherNames>McMichael AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>9F47EDDFAFD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DB22957-289D-4DB2-BBE5-6678B1048E41</gtr:id><gtr:title>Functional analysis of dendritic cell-T cell interaction in sarcoidosis.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eca0ef3cb9f324316ac029162c6addd2"><gtr:id>eca0ef3cb9f324316ac029162c6addd2</gtr:id><gtr:otherNames>Kulakova N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>60D3D7B3826</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51C77A5E-19A9-4727-9310-B63A0978BF10</gtr:id><gtr:title>Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4633cc5115042b7d5befd3c4cfa05c5b"><gtr:id>4633cc5115042b7d5befd3c4cfa05c5b</gtr:id><gtr:otherNames>Petrovski S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>XEfWtie7m2y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA8536E2-DB04-49EC-A96C-DB4A599A5C20</gtr:id><gtr:title>Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/976eaddf2bc9b147e2b76a86d7e294d5"><gtr:id>976eaddf2bc9b147e2b76a86d7e294d5</gtr:id><gtr:otherNames>Yang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>4A0ED501E23</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AB728F3-D05E-44CF-9A30-EE16007BF0A8</gtr:id><gtr:title>Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bde23452702f3d087e5f35cb87dd0e1"><gtr:id>1bde23452702f3d087e5f35cb87dd0e1</gtr:id><gtr:otherNames>Zhang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>CPRW1YaUMb9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EAFD20A-2900-4CE7-B540-FC6036102362</gtr:id><gtr:title>An early HIV mutation within an HLA-B*57-restricted T cell epitope abrogates binding to the killer inhibitory receptor 3DL1.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4657e715e0a0f585fce086332255e435"><gtr:id>4657e715e0a0f585fce086332255e435</gtr:id><gtr:otherNames>Brackenridge S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>LDvJQwNk3iZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9901DF4-C6BD-4196-93CE-F89E34638F16</gtr:id><gtr:title>HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7759ddd6dc440db295f95c228dae60dd"><gtr:id>7759ddd6dc440db295f95c228dae60dd</gtr:id><gtr:otherNames>Wood N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>CC6DA6A5427</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12014F80-AFC1-4FBF-99B8-F1DD2A1A227F</gtr:id><gtr:title>Early acquisition of cytolytic function and transcriptional changes in a primary CD8+ T-cell response in vivo.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b0ab83ce5a962ead03102dd5b014052"><gtr:id>5b0ab83ce5a962ead03102dd5b014052</gtr:id><gtr:otherNames>Chiu C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>4ECEE576C44</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>645053DE-E4AB-4C4B-9597-33A6A232769C</gtr:id><gtr:title>Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/976eaddf2bc9b147e2b76a86d7e294d5"><gtr:id>976eaddf2bc9b147e2b76a86d7e294d5</gtr:id><gtr:otherNames>Yang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_14011_21_22711904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80706F9C-881A-4E2D-A2B6-C782CBC73736</gtr:id><gtr:title>Quantitating T cell cross-reactivity for unrelated peptide antigens.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cd735d2c7ec2a06f5c43d6198a3ebae"><gtr:id>7cd735d2c7ec2a06f5c43d6198a3ebae</gtr:id><gtr:otherNames>Ishizuka J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>2DE1D9D6D08</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>585536D6-89DE-44E0-B2C7-C23A1C085316</gtr:id><gtr:title>Avian influenza A(H5N1) viruses can directly infect and replicate in human gut tissues.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed8abc0535485a4ce59719db1a799a06"><gtr:id>ed8abc0535485a4ce59719db1a799a06</gtr:id><gtr:otherNames>Shu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>ikfoeBi188z</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1495B0E4-847E-4BD2-830B-0F21742D3472</gtr:id><gtr:title>Design and pre-clinical evaluation of a universal HIV-1 vaccine.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94b2f585dc4d4206ae8515f3b522e7d5"><gtr:id>94b2f585dc4d4206ae8515f3b522e7d5</gtr:id><gtr:otherNames>L?tourneau S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>8382B1DC52A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4C68879-2DCE-42F9-90DD-2F467B939890</gtr:id><gtr:title>Blocking development of a CD8+ T cell response by targeting lymphatic recruitment of APC.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c5a9c8be01312f74038c2cc7616212f"><gtr:id>0c5a9c8be01312f74038c2cc7616212f</gtr:id><gtr:otherNames>Teoh D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>AF102F8CADC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C31F29F-61C3-4AF7-9197-6345656A236C</gtr:id><gtr:title>Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02f3b3926bb0e48897a8bbe9f8dcb3d1"><gtr:id>02f3b3926bb0e48897a8bbe9f8dcb3d1</gtr:id><gtr:otherNames>Schneidewind A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>40BAC8B8A72</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13355229-5186-40E7-BAB2-445CD0F3C5B7</gtr:id><gtr:title>Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8af3eae12e9c3485ab2e2ff801c5b9f"><gtr:id>a8af3eae12e9c3485ab2e2ff801c5b9f</gtr:id><gtr:otherNames>Cebere I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>AAE850D2396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22D291EB-C54F-4060-8EEC-8B35DBA7C6CC</gtr:id><gtr:title>The structural dynamics and energetics of an immunodominant T cell receptor are programmed by its Vbeta domain.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cd735d2c7ec2a06f5c43d6198a3ebae"><gtr:id>7cd735d2c7ec2a06f5c43d6198a3ebae</gtr:id><gtr:otherNames>Ishizuka J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>9455C89F1E3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC5E97FA-48E6-41BE-874B-D177A697A659</gtr:id><gtr:title>CCL3L1 and HIV/AIDS susceptibility.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd89e08bfb4c7846101701582e9c34f6"><gtr:id>bd89e08bfb4c7846101701582e9c34f6</gtr:id><gtr:otherNames>Urban TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>F4A1F268664</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB06DD74-E0A0-49D4-B494-2300ECC5BCB1</gtr:id><gtr:title>Loss of DNAM-1 contributes to CD8+ T-cell exhaustion in chronic HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2563e7fdb80c5c8d1ebbd09e92583552"><gtr:id>2563e7fdb80c5c8d1ebbd09e92583552</gtr:id><gtr:otherNames>Cella M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>AC9brq4DJjc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A676C294-F8D2-4593-8364-FD0B6B193458</gtr:id><gtr:title>The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29a1e8da928d5a9b83265addc5a6a688"><gtr:id>29a1e8da928d5a9b83265addc5a6a688</gtr:id><gtr:otherNames>Walley NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>A65A346C33C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2309C31-E624-4707-A99D-6DC9864A05F3</gtr:id><gtr:title>Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbf753ff76c52dde307df3f4970ae408"><gtr:id>dbf753ff76c52dde307df3f4970ae408</gtr:id><gtr:otherNames>Kramer HB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>LBK9HacVTKg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF633CDB-EC04-4EE0-AE57-73B961512837</gtr:id><gtr:title>Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3eae989d7fe2595c2c6dea57f94ec9e5"><gtr:id>3eae989d7fe2595c2c6dea57f94ec9e5</gtr:id><gtr:otherNames>Wu J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>Zeeuhvh3yB9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAA18D16-8775-4247-BB38-C68380C84AF1</gtr:id><gtr:title>Triple bypass: complicated paths to HIV escape.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14eeb8916c21a02f9a4f13433a8408c8"><gtr:id>14eeb8916c21a02f9a4f13433a8408c8</gtr:id><gtr:otherNames>McMichael AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>299DCC2BBA9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFACA11A-7F1F-4286-B689-5B132A31E29A</gtr:id><gtr:title>Interleukin-10 responses to therapeutic vaccination during highly active antiretroviral therapy and after analytical therapy interruption.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/976eaddf2bc9b147e2b76a86d7e294d5"><gtr:id>976eaddf2bc9b147e2b76a86d7e294d5</gtr:id><gtr:otherNames>Yang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>72F80048E77</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>884764E7-6255-45CA-8022-E04E1B626F36</gtr:id><gtr:title>Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e7b5bfbb7d685aef71a3b09b947ac84"><gtr:id>0e7b5bfbb7d685aef71a3b09b947ac84</gtr:id><gtr:otherNames>Howles S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>jfphcatxgiY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A311C2C4-A9D5-4DE9-9743-E0B35A695320</gtr:id><gtr:title>Highly avid, oligoclonal, early-differentiated antigen-specific CD8+ T cells in chronic HIV-2 infection.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0ae9c03e19152fa146debeb3e0a9814"><gtr:id>c0ae9c03e19152fa146debeb3e0a9814</gtr:id><gtr:otherNames>Leligdowicz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>nP4biUXKbJ6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBD9932C-C1A4-4394-B102-73597F7C9388</gtr:id><gtr:title>Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3744dbe1aa8c3b72c3e4f82972a51aaa"><gtr:id>3744dbe1aa8c3b72c3e4f82972a51aaa</gtr:id><gtr:otherNames>Ho LP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>C6D4DF81EB6</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U137884177</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>